Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

Clinical trial NCT05024552 · RECRUITING

Trial details

NCT number: NCT05024552
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia With FLT3/ITD Mutation

Start date: 2022-02-25
Primary completion: 2027-02-15
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.